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Abstract: The development of new therapeutic options against Clostridioides difficile (C. difficile)
infection is a critical public health concern, as the causative bacterium is highly resistant to
multiple classes of antibiotics. Antimicrobial host-defense peptides (HDPs) are highly effective
at simultaneously modulating the immune system function and directly killing bacteria through
membrane disruption and oxidative damage. The copper-binding HDPs piscidin 1 and piscidin
3 have previously shown potent antimicrobial activity against a number of Gram-negative and
Gram-positive bacterial species but have never been investigated in an anaerobic environment.
Synergy between piscidins and metal ions increases bacterial killing aerobically. Here, we performed
growth inhibition and time-kill assays against C. difficile showing that both piscidins suppress
proliferation of C. difficile by killing bacterial cells. Microscopy experiments show that the peptides
accumulate at sites of membrane curvature. We find that both piscidins are effective against epidemic
C. difficile strains that are highly resistant to other stresses. Notably, copper does not enhance piscidin
activity against C. difficile. Thus, while antimicrobial activity of piscidin peptides is conserved in
aerobic and anaerobic settings, the peptide–copper interaction depends on environmental oxygen to
achieve its maximum potency. The development of pharmaceuticals from HDPs such as piscidin will
necessitate consideration of oxygen levels in the targeted tissue.
Keywords: host defense peptides; membrane activity; copper; piscidins; Clostridioides difficile
1. Introduction
Clostridioides (formerly Clostridium) difficile infection (CDI), whose symptoms can include
inflammation, profuse diarrhea, and pseudomembranous colitis, has been recognized as an urgent
public health threat in the United States and other industrialized nations [1,2]. CDI is primarily
a hospital-acquired disease, as disruption of the native gut microbiota by prior antibiotic usage is the
major risk factor for C. difficile colonization, although the number of community-acquired infections
has increased in recent years [3,4]. The severity of CDI has also increased during the 21st century with
the emergence of so-called “hypervirulent” epidemic ribotypes of the bacterium, most notably ribotype
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027, that are associated with higher levels of disease recurrence and death in infected patients [3,5–7].
C. difficile is resistant to several families of antibiotics, including penicillin-family beta lactams and
fluoroquinolones, and is increasingly resistant to next-generation therapeutics including fidaxomicin
and vancomycin [6,8,9]. Currently, the most clinically effective treatment for CDI is replenishment of
the protective gut microbiota through fecal transplants. As these procedures have a high inherent risk of
introducing uncharacterized pathogens and are not recommended for immunocompromised patients,
there is great interest in the development of new strategies for prevention and treatment [10–13].
C. difficile persists in the environment in the form of metabolically dormant spores, which are
highly resilient to chemical and physical stresses and remain viable for months [14,15]. If mammals
ingest these spores, amino acids and bile salts in the digestive system trigger their germination into
metabolically active vegetative cells [16–18]. Vegetative C. difficile often cannot integrate well into
the diverse, metabolically efficient microbial ecosystem of a healthy intestinal microbiome but can
take advantage of the loss of bacterial species diversity and rise in nutrient availability induced by
antibiotic exposure to establish colonization [19–22]. C. difficile colonization triggers the innate immune
response, including the release of reactive oxygen species (ROS) and cationic host defense peptides
(HDPs) [23–25]. These antimicrobial peptides can kill bacterial cells directly through a number of
mechanisms, attacking the cell membrane and/or intracellular targets, and indirectly by activating
the host innate immune response [26–29]. As these peptides have multiple cellular targets, bacteria
cannot quickly develop or transmit genetically encoded resistance to them, and they are a promising
precursor for the development of stand-alone antibiotics or adjuvants designed to work synergistically
with existing antibiotics [30,31].
Piscidins are a family of HDPs found in teleost (bony) fish species with demonstrated efficacy
against a wide range of bacteria and viruses [32–35]. The piscidins p1 (FFHHIFRGIVHVGKTIHRLVTG)
and p3 (FIHHIFRGIVHAGRSIGRFLTG), which are derived from the mast cells of hybrid striped sea
bass, exhibit broad spectrum antibacterial activity although their mechanisms of action differ [36,37].
Both peptides localize to bacterial cell membranes and are internalized at sub-lethal concentrations.
While p1 is more damaging to membrane integrity than p3, the latter is more disruptive to DNA [36].
Furthermore, studies done on live bacteria and model membranes indicate that the peptides, especially
p1, take advantage of lipid heterogeneity to deploy their mechanism of membrane disruption [36,38].
Recently, we demonstrated that under aerobic conditions both peptides use their amino-terminal copper-
and nickel-binding (ATCUN) motifs to coordinate Cu2+ with picomolar affinity [37,39]. Piscidin-copper
complexes form ROS and exhibit nuclease activity against double stranded DNA, resulting in increased
lethality against multiple bacterial species [37]. Such copper-ATCUN complexes can serve as sources
of oxidative stress, increasing peptide lethality against bacteria in an aerobic environment [40–42].
Oxidative stress can be harmful or lethal to organisms, depending on their oxidative stress tolerance.
Obligate anaerobes such as Clostridia are considered completely intolerant to oxygen, although they
can employ scavenger and reductase enzymes to survive transient exposure to environmental oxygen
or immune-mediated oxidative bursts [15,23,43–45]. Application of antimicrobial peptides sensitizes
C. difficile to antibiotics, although epidemic strains from ribotype 027 are less sensitive than other
strains [31,46].
Importantly, as HDPs, piscidins have immunomodulatory effects. In particular, our investigations
have demonstrated that both p1 and p3 induce chemotaxis in neutrophils [39]. These effects are
exclusively mediated by formyl peptide receptors 1 and 2 (FPR1 and FPR2), both of which are G-protein
coupled receptors (GPCRs) that play important functions in the immune system [47–51]. Interestingly,
Cu2+-coordination decreases the chemotactic effects of p1 and p3, suggesting a regulatory effect of
copper between the direct and indirect antimicrobial effects of the peptides [39]. Given the role of
FPR2 for the resolution of inflammation, it has become an important drug target [47–49]. P1 has
also been shown to decrease the inflammatory response through a process that may involve binding
lipopolysaccharides and decreasing toll-like receptor (TLR)-mediated inflammatory pathways [52,53].
The immunomodulatory properties of HPDs such as piscidin have emerged as an important topic
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of research given that these effects are indirect, and thus unlikely to activate mechanisms of drug
resistance observed with traditional antibiotics that directly attack bacteria [54–59]. In addition, HDP
modulation of the inflammatory immune response can mitigate infection symptoms and has been
shown to reduce toxin-dependent inflammation in mouse models of C. difficile infection [60].
As indicated above, the antimicrobial effects of piscidin have previously been measured in aerobic
environments. However, there is a ten-fold range of partial oxygen pressure among the tissues of
the human body, with organs such as the large intestine providing a habitat for anaerobic microbes,
both commensal and pathogenic [61]. Here, we report that the antimicrobial activity of p1 and p3
differ in aerobic and anaerobic environments. In an anaerobic environment, both p1 and p3 are
incorporated into C. difficile cells, inhibit bacterial proliferation, and are highly toxic against actively
dividing C. difficile. Both peptides associate extensively with bacterial cell membranes, exhibiting
preferential localization at sites of high curvature such as cell poles and septa. In contrast to previously
observed aerobic data, anaerobic piscidin antibacterial activity does not appear to be enhanced by
metal complex formation. Our findings suggest that the mechanism by which these peptides induce
bacterial cell death is influenced by the availability of environmental oxygen. It is clear that future
mechanistic investigations of HDPs focused on potential medical applications must account for oxygen
levels at the desired site of action in order to accurately model antimicrobial activity.
2. Results
2.1. Piscidins Are Incorporated into C. difficile and Appear to Localize to Sites of Membrane Curvature
Confocal microscopy of fixed bacterial cells exposed to fluorescently labeled p1 and p3 has
previously shown that they enter both Gram-negative and Gram-positive bacterial cells and appear
to be concentrated at bacterial nucleoids and cell septa [36,39]. We exposed live C. difficile R20291
cells to 0.75 µM 5-carboxytetramethylrhodamine (TAMRA)-labeled p1 and p3 and observed peptide
uptake and localization in unfixed live cells. As C. difficile exhibits green autoflouresence, the red
TAMRA labeling was distinct from any intrinsic signal produced by the cells [62]. Exponential-phase
cells and peptides were mixed and sealed within microscopy chambers in an anaerobic chamber
and then transported to the microscope, resulting in a 6-min delay between the onset of peptide
exposure and the first image [63]. Mean fluorescence intensity within cells was stable over the course
of 1 h of monitoring, indicating that peptide incorporation into cells occurs within the first few min of
exposure (Figure 1A,B). Peptide integration appeared to be complete within 6 min even at lower peptide
concentrations of 0.25 and 0.075 µM (data not shown). The addition of additional unlabeled peptide or
unlabeled peptide complexed with Cu2+ did not increase fluorescence intensity, and thus there was no
evidence of potential cooperativity in peptide uptake. There were distinct fluorescent puncta at the
septa of predivisional cells (Figure 1C,E,F), consistent with prior observations in Escherichia coli (E. coli)
and Bacillus megaterium (B. megaterium) [36]. In addition, there were fluorescent puncta at cell poles,
suggesting that piscidins generally localize to sites of high curvature (Figure 1D). While unlabeled cells
were motile and maintained rod-like shapes, many of the fluorescently labeled cells exhibited curvature
or surface irregularities suggestive of cell envelope damage (Figure 1E). Performing these experiments
on live cells allowed real-time observation of cellular response to peptide intoxication. We observed
a motile chain of predivisional rod-shaped cells over the course of 10 min (Figure 1G). During this
time, the chain of cells took up labeled p1 at one pole and subsequently developed progressively
severe curvature at cell septa and separated into smaller fragments (Figure 1G). The resulting pieces
were asymmetrically curved and non-motile, indicating that lysis rather than healthy cell division
had occurred.
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μM TAMRA-labeled p3; (E) 0.75 μM TAMRA-labeled p1 plus 2.25 μM unlabeled p1; (F) 0.75 μM 
TAMRA-labeled p1 plus 0.75 μM unlabeled p1. (G) Timecourse showing the rupture of a pre-
divisional cell labeled with 0.75 μM TAMRA-labeled p1 plus 0.75 μM unlabeled p1. Scale bars in 
panels (C–F) represent 10 μm. Scale bar in panel (G) represents 5 μm. 
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Figure 1. Incorporation of TAMRA-piscidin into live C. difficile. (A,B) Fluorescent signal per cell of
0.75 µM TAMRA-labeled p1 (A) and p3 (B) mixed with live C. difficile R20291. Cells had already reached
maximum peptide incorporation by the time recording began, roughly 6 min after peptides and cells
were mixed. Addition of unlabeled peptide, in the presence or absence of equimolar amounts of copper
sulfate, did not cooperatively increase peptide incorporation. (C–F) Representative images of C. difficile
labeled with: (C) 0.75 µM TAMRA-labeled p1 plus 0.75 µM unlabeled p1; (D) 0.75 µM TAMRA-labeled
p3; (E) 0.75 µM TAMRA-labele p1 plus 2.25 µM unlabeled p1; (F) 0.75 µM TAMRA-labeled p1 plus
0.75 µM unlabeled p1. (G) Timecourse showing the rupture of a pre-divisional cell labeled with 0.75 µM
TAMRA-labeled p1 plus 0.75 µM unlabeled p1. Scal bars in panels (C–F) represent 10 µm. Scale bar in
panel (G) represents 5 µm.
2.2. Piscidins Prevent C. difficile Proliferation
In order to measure the inhibitory effects of piscidin peptides on C. difficile growth we inoculated
C. difficile strains 630∆erm and R20291 into a medium containing the peptides. C. difficile 630∆erm is
an erythromycin-sensitive d rivative of the refer nce strain C. difficile 630, while R20291 is an epidemic
strain solat d from a 20 3–2005 hospital outbreak of C. difficile infectio in the United Kingdom [64,65].
R20291 is a s -called “hypervirulent” strain of ribotype 027 and i more resistant than 630 to multiple
classes of antibiotics including clindamycin and ciprofloxacin [66–69]. The presence of piscidin peptides
prevented C. difficile proliferation. Notably, R20291 was as susceptible as 630∆erm to growth inhibition
by piscidin. p1 inhibited proliferation of both strains at concentrations at or above 4.00 µM and p3
inhibited growth at or above 8.00 µM (Figure 2).
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Figure 2. Piscidins inhibit C. difficile growth. Optical densities of overnight C. difficile 630∆erm and
R20291 cultures grown in the presence of the indicated concentrations of piscidins. Data shown are the
means and standard deviations of four biologically independent samples.
2.3. Piscidins Reduce Established C. difficile Populations
Growth inhibition assays do not distinguish between substances that kill cells and bacteriostatic
substances that inhibit growth only if compounds are present in sufficient quantities prior to bacterial
proliferation. To confirm that piscidins are capable of reducing the number of viable cells in established
bacterial populations, we performed time-kill assays to confirm that the number of viable C. difficile
R20291 cells in exponentially growing culture decreases with exposure to p1 and p3 at sub-inhibitory
concentrations. As shown in Figure 3, both p1 and p3 reduce C. difficile viability at half of the concentration
needed to inhibit bacterial growth. The addition of 2.00 µM p1 significantly reduces the number of
viable cells in the culture within 30 min, with continued loss of colony forming units over the course of
4 h (Figure 3A). Similarly, incubation with 4.00 µM p3 significantly reduced the number of viable cells
within 30 min (Figure 3B). The bacterial killing by both p1 and p3 against E. coli in aerobic environments
is exacerbated by the addition of equimolar copper, which complexes with the peptides, resulting in
covalent damage to lipids and DNA [37]. We investigated the effect of adding copper sulfate to the
anaerobic C. difficile killing assays at the same molar concentration as the piscidins. The addition of copper
ions had no observable effect on p1 lethality at any of the timepoints examined (Figure 3A). Copper
did appear to accelerate killing by p3 at 30 min and 2 h post-treatment, but the differences between
peptide alone and peptide with copper had disappeared by 4 h post-treatment (Figure 3B). To investigate
the possibility that copper ions were being chelated by other factors present in the tryptone-yeast (TY)
medium and not actually forming complexes with piscidins, we repeated the assays with pre-formed
piscidin-copper complexes. Copper allowed to form complexes with p1 prior to addition to the bacteria
cultures still had no additional impact on p1 killing of C. difficile (Figure 3A) compared to apo p1.
Pre-formed p3-copper complexes behaved like p3 in the absence of copper, killing C. difficile more slowly
than p3 with copper added separately, but differences between the two conditions disappeared within
4 h (Figure 3B). This confirms that copper does not enhance the antimicrobial effects of piscidins under
anaerobic conditions.
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Figure 3. Copper does not accelerate anaerobic C. difficile killing by piscidins. Time-kill assays
comparing viable colony forming units per milliliter (CFU/mL) of bacterial culture before exposure to
p1 (A) and p3 (B) with the CFU/mL 30 min, 2, and 4 h post-exposure. Cells were exposed to peptides
(p1 and p3), peptides and equimolar copper sulfate added simultaneously (p1 + Cu and p3 + Cu), and
peptides allowed to form piscidin-copper complexes in an aerobic environment prior to addition to the
anaerobic bacterial cultures ((p1Cu) and (p3Cu)). CFU/mL in treated samples were compared to those
in untreated samples and to each other using two-way ANOVA with Tukey’s post-test comparison. nt,
not treated; n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
2.4. Copper Is Toxic to Anaerobically Growing C. difficile
It has been previously suggested the antimicrobial synergy of ATCUN-containing HDPs depends
upon environme tal dioxygen, which could account for the inability of c pper ions to e h ce piscidin
activity against C. difficile [40,70,71]. To define the effects of copper alone against C. difficile, we determined
that the copper concentration of the TY growth medium used to culture C. difficile under n erobic
conditions (Figure 4A) is 1.46 µM, which is lower than that of the Mueller-Hinton broth previously used
to culture E. coli and Pseudomonas aeruginosa under aerobic conditions [37,72]. We found that copper salts
are capa le of inhibiting C. difficile growth at the same concentrations used in the time-kill assays with
piscidins. The epidemic strain R20291 is less susceptible to copper inhibition that the historical strain
630∆erm (Figure 4B). Actively dividing R20291 cells in the exponential phase are also killed by exposure
to micromolar concentrations of copper sulfate (Figure 4C).
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Figure 4. Copper is still antimicrobial in anaerobic environments. (A) Copper concentration of TY
medium. (B) Optical densities of overnight C. difficile 630∆erm and R20291 cultures grown in the
presence of the indicated concentrations of copper sulfate. Data shown are the means and standard
deviations of four biologically independent samples. (C) Time-kill assays comparing viable colony
forming units per milliliter (CFU/mL) of bacterial culture before exposure to the indicated concentrations
of copper sulfate with the CFU/mL 30 min, 2, and 4 h post-exposure. CFU/mL in treated samples
were compared to those in untreated samples and to each other using two-way ANOVA with Tukey’s
post-test comparison. nt, not treated; n.s., not significant; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
3. Discussion
The development of new therapies to combat antibiotic-resistant infections, including C. difficile
infection, is an urgent public health priority. Antimicrobial peptides capable of simultaneously killing
bacterial pathogens a d stimulating the host innate system are a promising avenue for the development
of new antimicrobial therapies. Piscidins previously showed efficacy against Gram-negative a d
-positive bacteria in aerobic environments [37]. Here, we investigated their effect o anaerobic bacteria.
While piscidins are still highly lethal against C. difficile growing anaerobically, we found that piscidin
growth inhibition and killing against C. difficile were ot enhanced by the addition of Cu2+. This is
true despite the fact t at copper alone is capable of inhibiting C. difficile growth and killing actively
growing C. difficile cells. While in aerobic environments, the bacterial response to piscidins with
Cu2+ is greater than that to either piscidins or copper alone, it appears that the anaerobic response to
piscidin with copper is less than the sum of t e parts, and thus does not feature the synergistic effects
observed aerobically.
Bacteria employ general stress response pat ways that can be activate by multiple diverse
extracellular stresses. Bacterial cells that have previously been exposed to an extracellular stress,
such as starvation or oxidative stress, demonstrate increased resilience against unrelated threats,
such as antibiotic exposure [73,74]. The fact that the C. difficile strains 630∆erm and R20291 exhibit
identical inhibition in response to p1 and p3, but differential inhibition to copper alone, suggests
Int. J. Mol. Sci. 2019, 20, 5289 8 of 14
that piscidins and copper inhibit bacterial growth and viability by different mechanisms. This makes
sense because Cu2+ has no specificity while piscidin does. It should be noted that free Cu2+ in vivo
is highly toxic to mammalian as well as bacterial cells, and complexation by HDPs such as p1 and
p3 can provide the critical specificity of targeting the metal ions to bacterial rather than host cells.
HDPs are a viable treatment option against both aerobic and anaerobic bacteria, and in the case of
C. difficile, it is extremely encouraging that the epidemic strain R20291 is just as susceptible to HDP
inhibition and killing as the less robust 630∆erm strain. As the symptoms of C. difficile infection are
largely inflammatory, and treatments based on piscidins could potentially reduce inflammation while
killing the causative pathogen, this is a very promising strategy to pursue. However, it is clear that
while clinical antibiotics derived from HDPs would benefit from the inclusion of copper in tissues with
high levels of oxygen, such as the lungs, antibiotics targeted to less aerobic tissues, such as the kidneys
or large intestine, may not. Future work to investigate the interaction of piscidins with C. difficile in
animal models of infection will be necessary to determine whether copper could or should be included
with the peptides. More broadly, it appears that clinical treatments developed from HDPs should be
designed in a tissue-specific manner, as metal ion adjuvants may be beneficial or necessary in some
organs and unneeded in others, based on the oxygen levels at the site of activity.
4. Materials and Methods
4.1. Materials, Chemicals, Bacterial Strains and Growth Conditions
Materials and chemicals were purchased from Fisher Scientific (Hampton, NH, USA) unless
otherwise indicated. The bacterial strains used in this study are listed in Table S1. C. difficile 630∆erm
and R20291 were maintained on brain-heart infusion supplemented with 5% yeast extract (BHIS)
agar plates and liquid cultures were grown in TY medium [16,75,76]. All anaerobic bacterial culture
took place at 37 ◦C in a Coy anaerobic chamber (Coy Laboratory Products, Grass Lake, MI) with
an atmosphere of 85% N2, 10% CO2, 5% H2. All plastic consumables were allowed to equilibrate in the
anaerobic chamber for a minimum of 72 h.
4.2. Peptide Synthesis
Caboxyamidated p1 (MW 2571) and p3 (MW 2492) were synthesized using Fmoc chemistry at
the University of Texas Southwestern Medical Center (Dallas, TX, USA). For the TAMRA-labeled
forms of the peptides, the fluorescent label was attached to the amino-end of the peptides before
cleavage from the resin. The peptides were purified at William and Mary on a Waters HPLC system
using a C18 X-Bridge Waters column (Milford, MA, USA) and acetonitrile/water gradient acidified
with 0.1% trifluoroacetic acid, as previously described [77,78]. After removal of the organic phase,
the peptides were lyophilized. Next, they were dissolved in dilute HCl and dialyzed to remove residual
trifluoroacetic acid. The purification steps yielded 98% pure peptides based on HPLC chromatograms
and mass spectrometry data. HPLC chromatograms and mass spectra collected at William and Mary on
the purified peptides are included in the Supplementary Information (Figures S1 and S2). The purified
peptides were dissolved in nanopure water. The concentrations of p1 and p3 were determined by
amino acid analysis at the Texas A&M Protein Chemistry Center (College Station, TX, USA). Metallation
of each peptide was achieved when an equimolar of CuSO4 was added to the medium (see below).
For the TAMRA-labeled peptides, the absorbance at 547 nm was used to quantify their concentrations.
To avoid photobleaching of the fluorescent probe, the TAMRA-labeled peptides were protected from
light by wrapping containers with foil.
4.3. Microscopy
Live-cell, time-lapse, wide-field fluorescence, and differential interference contrast (DC) microscopy
of the interaction between TAMRA-labeled piscidin peptides and C. difficile R20291 bacteria was performed
on a Nikon Ti-E inverted microscope equipped with apochromatic TIRF 60X oil immersion objective lens
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(N.A. 1.49), pco.edge 4.2 LT sCMOS camera, and SOLA SE II 365 Light Engine as well as complementary
DIC components (Nikon Instruments Inc, Melville, NY, USA). Mid-logarithmic phase cells and peptides
at the indicated concentration were mixed inside the anaerobic chamber and injected into home-built
anaerobic rose-type imaging chambers as previously described [63]. Imaging chambers were removed
from the anaerobic chamber and placed on the microscope. The microscope was maintained at 37 ◦C
using a home-built enclosure and a Nevtek Air Stream microscope stage warmer (Nevtek, Williamsville,
VA, USA). Nikon Perfect Focus system (Nikon Instruments Inc, Melville, NY, USA) was employed
to eliminate focal drift during recordings. Movies consisting of a fluorescence and DIC image each
minute for 60 min were then recorded for each condition. Movies started 6–8 min after the bacteria and
peptide were mixed. Data analysis was performed using the Nikon Elements imaging suite. During
the recordings the amount of fluorescence background increased with time, presumably as peptide
was deposited on the coverslip surface. During analysis this background change was corrected using
background-leveling tools, then a second rolling-ball type background correction was used to remove
imaging artifacts. A thresholded binary mask was then applied to the fluorescence images to isolate and
count each fluorescent object (peptide-labeled bacteria) in the movie. Fluorescence levels of objects were
monitored as a function of time.
4.4. Growth Inhibition Assays
Two-fold dilution series of TY medium containing the indicated concentrations of peptide and/or
copper salts were prepared in sterile 96-well plates as detailed in Wiegand et al. [79]. Wells containing
200 µL of medium were inoculated with 20 µL of saturated overnight culture of C. difficile 630∆erm
or R20291 containing approximately 108 CFU/mL and incubated anaerobically for 16 h at 37 ◦C.
Closed microplates were removed from the anaerobic chamber and the outsides of the plates were
disinfected with 10% bleach before examination to determine the minimum concentration of each
peptide and/or metal ion sufficient to complete inhibit visible growth. Culture density at 630 nm was
measured in a BioTek (Winooski, VT, USA) microplate reader. As removal from the anaerobic chamber
killed the anaerobic C. difficile bacteria, we were not able to plate samples to determine CFU/mL after
spectroscopic measurements. Inhibitory concentrations were reported as the peptide concentration
necessary to reduce the overnight OD630 by at least 50% from that of untreated samples. Data reported
are the means and standard deviations of four biologically independent samples.
4.5. Time-Kill Assays
3 mL of TY media were inoculated with single colonies of C. difficile R20291 and allowed to grow
at 37 ◦C to an optical density at 600 nm (OD600) of 0.5–0.7. At the onset of the experiment 20 µL
aliquots were removed from the exponentially growing culture and inoculated into fresh TY medium
containing the indicated concentration of peptide and/or copper sulfate (CuSO4). The final volume was
adjusted to 1 mL with fresh TY medium. After 0, 0.5, 2, and 4 h of incubation at 37 ◦C, 10 µL aliquots
were removed for serial 10-fold dilution in TY. 106 dilutions were plated in duplicate on BHIS agar
plates for colony enumeration. Colony forming units (CFU) were counted after 24 h. Data reported
are the averages of three biologically independent samples measured in duplicate. Treated samples
were compared to untreated samples and to each other by two-way ANOVA using Tukey’s multiple
comparison test with Prism (GraphPad Software, San Diego, CA, USA).
4.6. Atomic Absorption Spectroscopy
The copper concentration in TY medium was measured using an AA-7000 atomic absorption
spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD, USA) with a hollow cathode
lamp using an acetylene flame [80]. Copper from TY medium was detected at 324.8 nm and quantified
using a standard curve of copper chloride (CuCl2) diluted in water.
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